MIV-701

MIV-701 is a selective and potent small molecule inhibitor of the protease cathepsin K. Cathepsin K plays a key role in the degradation of bone matrix proteins such as collagen, gelatin, and elastin. By inhibiting cathepsin K, MIV-701 reduces bone resorption and has been investigated primarily for the treatment of osteoporosis. The drug was developed by Medivir and reached phase 1 clinical trials for osteoporosis and postmenopausal osteoporosis but was later discontinued in these indications. Preclinical studies also explored its potential use in bone cancer and osteoarthritis. Additionally, under the code name VBX-1000, it has been studied for periodontal disease in dogs[1][2][3][4].